Processing, please wait...
5 videos 1 badge
Premium

Dr Michael BENZAQUEN

Dermatologist
France

I completed medical education at the Faculty of Medicine of Marseille, Aix-Marseille University (Marseille, France), and ranked first among 3000 students in the first year of medical school. I then completed my residency in Dermatology at Assistance Publique Hôpitaux de Marseille, before a fellowship in the department of Dermatology at Hôpital Nord de Marseille. My professional experiences abroad in Columbia University (New York City, USA) and Inselspital - University Hospital of Bern (Bern, Switzerland) improved my clinical skills and knowledge in Dermatology, as well as my success in ECFMG certification (USA). I graduated from several inter-university diplomas in Internal Medicine, Pediatric Dermatology, Dermatological Laser and Dermatological Surgery. My works have been published in international peer-reviewed journals and I am regularly invited as speaker in international congresses. I investigated in various fields, ranging from infectious and inflammatory diseases to onco-dermatology, laser and surgery. As the Vice-President of the Scientific Council of the French Laser Group, I encouraged young dermatologists in learning and practicing dermatological lasers. I am currently working as clinical chief in the department of dermatology of Inselspital-University Hospital of Bern, Switzerland.

read more
add item add Michael BENZAQUEN

Michael BENZAQUEN's publications (25)

[Surgical training during dermatology internships in France: A national survey among young dermatologists].

May, 2020

read more

Annales de dermatologie et de venereologie

Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.

May, 2020

Regarding the rising incidence and the not negligible mortality, the treatment of cutaneous squamous-cell carcinoma (cSCC) has a high clinical relevance. Immune checkpoint inhibitors (ICI), especially anti-programmed cell death-1 receptor (anti-PD-1) antibodies such as pembrolizumab and cemiplimab have shown promising results in Phase 2 studies for patients with locally advanced and/or metastatic cSCC. We are presenting a review of the latest results in the treatment of cSCC with ICI. Patients with locally advanced or metastatic cSCC have been treated with cemiplimab 3 mg/kg every 2 weeks. For locally advanced cSCC, an objective response was observed in 44% of patients, 13% patients with a complete response, and 31% with a partial response. For metastatic patients, the overall response rate was 49.2%. The approved dose for cemiplimab in the United States and Europe is 350 mg every 3 weeks. These ICI seem to achieve higher response rates compared with epidermal growth factor receptor (EGFR) inhibitors, with a durable response superior to both chemotherapy and EGFR inhibitors. The side effect profile of anti-PD-1 antibodies appears to be favorable compared to chemotherapy. In this way, PD-1 inhibitors are expected to become the new gold-standard treatment for patients with locally advanced and metastatic cSCC. read more

Dermatologic therapy

Self-injection of a solution intended for topical use containing hyaluronic acid and vitamin B5.

Jul, 2020

read more

Clinical and experimental dermatology
Load more  

Michael BENZAQUEN's learned societies (5)